Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

B Schermers; V Franke; E A Rozeman; B A van de Wiel; A Bruining; M W Wouters; W J van Houdt; B Ten Haken; S H Muller; C Bierman; T J M Ruers; C U Blank; A C J van Akkooi

doi:10.1002/bjs.11168

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

Br J Surg. 2019 Apr;106(5):519-522. doi: 10.1002/bjs.11168. Epub 2019 Mar 18.

Authors

B Schermers^{1

2}, V Franke¹, E A Rozeman³, B A van de Wiel⁴, A Bruining⁵, M W Wouters¹, W J van Houdt¹, B Ten Haken², S H Muller⁶, C Bierman⁴, T J M Ruers^{1

2}, C U Blank³, A C J van Akkooi¹

Affiliations

¹ Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
² MIRA Institute, University of Twente, Enschede, the Netherlands.
³ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁴ Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁵ Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁶ Department of Clinical Physics, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Abstract

This pilot study explored the value of localized index node removal after neoadjuvant immunotherapy in patients with stage III melanoma, for use as a response indicator to guide the extent of completion lymph node dissection. Promising technology.

Publication types

Randomized Controlled Trial

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Female
Humans
Ipilimumab / therapeutic use*
Lymph Node Excision / instrumentation
Lymph Node Excision / methods*
Lymph Nodes / diagnostic imaging
Lymph Nodes / pathology
Lymphatic Metastasis
Magnetics
Male
Melanoma / diagnostic imaging
Melanoma / drug therapy*
Melanoma / pathology
Melanoma / surgery*
Middle Aged
Neoadjuvant Therapy*
Neoplasm Staging
Nivolumab / therapeutic use*
Pilot Projects
Ultrasonography

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab